Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
Authors
Keywords
-
Journal
OncoImmunology
Volume 6, Issue 3, Pages e1267891
Publisher
Informa UK Limited
Online
2017-03-10
DOI
10.1080/2162402x.2016.1267891
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
- (2016) Haidong Tang et al. CANCER CELL
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Blinatumomab: First Global Approval
- (2015) Mark Sanford DRUGS
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- FDA approves first bispecific
- (2015) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
- (2015) Thomas F. Gajewski SEMINARS IN ONCOLOGY
- Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody
- (2015) Mahiuddin Ahmed et al. OncoImmunology
- CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
- (2015) Margaret K. Callahan et al. Frontiers in Oncology
- HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
- (2014) J C Singh et al. BRITISH JOURNAL OF CANCER
- Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells
- (2014) T. T. Junttila et al. CANCER RESEARCH
- HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma
- (2014) Netanya I. Pollock et al. CLINICAL CANCER RESEARCH
- Regulatory T cells in cancer immunotherapy
- (2014) Hiroyoshi Nishikawa et al. CURRENT OPINION IN IMMUNOLOGY
- Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex
- (2014) S. M. Cheal et al. MOLECULAR CANCER THERAPEUTICS
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications
- (2014) C. Marcela Diaz-Montero et al. SEMINARS IN ONCOLOGY
- Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody
- (2014) H. Xu et al. Cancer Immunology Research
- Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression
- (2014) Damya Laoui et al. Frontiers in Immunology
- HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
- (2013) Allan Lipton et al. BREAST CANCER RESEARCH AND TREATMENT
- Biomarkers of drugs targeting HER-family signalling in cancer
- (2013) Filippo Montemurro et al. JOURNAL OF PATHOLOGY
- Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
- (2013) David A. Nathanson et al. SCIENCE
- The two sides of HER2/neu: immune escape versus surveillance
- (2013) Barbara Seliger et al. TRENDS IN MOLECULAR MEDICINE
- Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group
- (2012) David Ebb et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual targeting strategies with bispecific antibodies
- (2012) Roland Kontermann mAbs
- Ipilimumab in advanced melanoma
- (2012) Alberto Farolfi et al. MELANOMA RESEARCH
- MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
- (2012) C.-T. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets
- (2012) Maxim Yankelevich et al. PEDIATRIC BLOOD & CANCER
- Indoleamine 2,3 dioxygenase and metabolic control of immune responses
- (2012) David H. Munn et al. TRENDS IN IMMUNOLOGY
- Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB-RAG-2−/−IL-2Rγ−/− mice: A promising model for studying human disease
- (2011) Danieli Andrade et al. ARTHRITIS AND RHEUMATISM
- Targeting T Cells with Bispecific Antibodies for Cancer Therapy
- (2011) Lawrence G. Lum et al. BIODRUGS
- Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma
- (2011) N Rainusso et al. CANCER GENE THERAPY
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
- (2011) Devika Gajria et al. Expert Review of Anticancer Therapy
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression
- (2009) Nabil Ahmed et al. MOLECULAR THERAPY
- A modular IgG-scFv bispecific antibody topology
- (2009) Kelly Davis Orcutt et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Use of humanized severe combined immunodeficient mice for human vaccine development
- (2008) Gloria C Koo et al. Expert Review of Vaccines
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started